ArticleBiomolecules & therapeutics2026
Single-Cell Transcriptomics of Pyrimidine Salvage in HBV-Related HCC Reveals Prognostic and Immune Infiltration Features.
Article in Biomolecules & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is primarily caused by hepatitis B virus (HBV). The pyrimidine-salvage pathway (PSP) is crucial for tumor proliferation, but its prognostic and immunomodulatory roles in HBV-HCC are unclear. By using single-cell transcriptomics, we investigated PSP signatures and their link to clinical outcomes and immune modulation in HBV-HCC. Data from XENA and GEO databases were analyzed. Malignant cell subpopulations were identified, and single-cell PSP activity was quantified. HBV-specific malignant subpopulations were characterized using the Ro/e metric. Cell-cell communication was analyzed. A prognostic model was developed and validated using a training cohort, and a nomogram was constructed. Immune infiltration, drug sensitivity, and the functional role of ferritin light chain (FTL) were examined experimentally. Malignant cells were classified into HBV⁻ and HBV⁺ subpopulations. The HBV⁺ group showed low PSP gene (PSPG) expression. The six-gene prognostic model demonstrated high predictive accuracy for 1-, 3-, and 5-year survival. High-risk patients had shorter survival and increased infiltration of macrophages, Tregs, and activated dendritic cells. Drug sensitivity analysis identified potential agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.